First Department of Otorhinolaryngology, Hippocration Hospital, Medical University of Athens, National and Kapodistrian University of Athens, Vas. Sofias 114, 11527, Athens, Greece.
World J Surg Oncol. 2020 Jan 9;18(1):8. doi: 10.1186/s12957-020-1785-3.
Data reporting the use of modified facelift incision (MFI) approach with or without superficial musculoaponeurotic system (SMAS) reconstruction in parotid malignancy are limited. To enhance the limited knowledge in this subject, the authors of the current study report quality data of MFI in patients with parotid malignancy with or without SMAS reconstruction.
We performed a retrospective review of parotid malignancy patients treated with the MFI over a 5-year period (2015-2019) in the 1st ENT University Department, University of Athens, Greece.
We identified five patients with parotid malignancy. We performed MFI parotidectomy in 5/5 patients and SMAS reconstruction in 2/5 patients. All tumors were classified as T1N0M0. After a mean follow-up of 43.6 months (minimum, 36; maximum, 55), we noted no recurrence. The patients reported no Frey's syndrome.
The authors of the current study suggest consideration of the MFI approach in parotid malignancy. A MFI approach should at least favor small parotid tumors without neck metastatic disease (T1cN0). Surgeons could also address larger tumors with a MFI approach. Surgeons should reconstruct the parotid lodge with a SMAS advancement flap in tumors not in proximity with the SMAS.
关于改良面中部提升切口(MFI)联合或不联合浅表肌肉腱膜系统(SMAS)重建在腮腺恶性肿瘤中的应用,相关数据报道有限。为了增加这一主题的有限知识,作者报告了 5 年来(2015-2019 年)在希腊雅典大学第 1 耳鼻喉大学系接受 MFI 治疗的腮腺恶性肿瘤患者的质量数据,其中部分患者联合或不联合 SMAS 重建。
我们对在希腊雅典大学第 1 耳鼻喉大学系接受 MFI 治疗的 5 例腮腺恶性肿瘤患者进行了回顾性研究。
我们共纳入了 5 例腮腺恶性肿瘤患者。5 例患者均接受了 MFI 腮腺切除术,2 例患者接受了 SMAS 重建。所有肿瘤均被归类为 T1N0M0。在平均随访 43.6 个月(最短 36 个月,最长 55 个月)后,我们未观察到复发。患者均未报告 Frey 综合征。
作者建议在腮腺恶性肿瘤中考虑采用 MFI 方法。MFI 方法至少应适用于无颈部转移性疾病(T1cN0)的小腮腺肿瘤。外科医生也可以采用 MFI 方法处理较大的肿瘤。对于与 SMAS 无毗邻关系的肿瘤,外科医生应采用 SMAS 推进皮瓣修复腮腺窝。